JERSEY CITY, N.J., Jan. 22, 2019 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ: SCYX), a biotechnology company delivering innovative
therapies for difficult-to-treat and often life-threatening
infections, today announced the appointment of Armando Anido to its Board of Directors. Mr.
Anido currently serves as Chairman and Chief Executive Officer of
Zynerba Pharmaceuticals (NASDAQ: ZYNE), a role he has held since
October 2014.
"2018 was a critical year for our company with the positive
results of our Phase 2 DOVE study in VVC, and we enter 2019 in a
position of strength with ongoing clinical activities for oral
ibrexafungerp in a variety of indications," said Guy Macdonald, Chairman of the Board of
SCYNEXIS. "As we near an initial NDA filing in VVC, anticipated in
the second half of 2020, and as we continue developing treatments
for hospital-based invasive fungal infections, we are excited to
leverage Armando's broad expertise, insights and guidance. On
behalf of my fellow Board members, I would like to welcome Armando
and look forward to his contributions as we carry out the important
work of bringing novel antifungal treatments to patients."
"I am impressed by SCYNEXIS's progress to date and honored to
join its Board at this exciting and transformative moment, as
SCYNEXIS advances ibrexafungerp across multiple indications
with a clear opportunity to address serious unmet medical needs,"
said Mr. Anido. "Given its late-stage asset and experienced
leadership team, the company is well positioned to bring
significant value to all key stakeholders – patients, physicians
and investors. SCYNEXIS is poised to make the first significant
advancement in more than two decades in the fight against severe
fungal infections, and I am looking forward to working with such an
impressive team and contributing to the company's future
success."
Mr. Anido has served as Chairman and Chief Executive Officer
(CEO) of Zynerba Pharmaceuticals since October 2014. Mr. Anido
has more than 30 years of executive, operational and commercial
leadership experience in the biopharmaceutical industry.
Prior to Zynerba, Mr. Anido served as CEO of two publicly traded
companies. Most recently, he was the CEO of NuPathe Inc., which was
acquired by Teva Pharmaceuticals in February
2014. At NuPathe, he led the company through FDA approval of
its lead product, Zecuity®, the first transdermal patch
for migraine, to pre-launch before the company's acquisition by
Teva. He also served as President and CEO of Auxilium
Pharmaceuticals, a specialty pharmaceutical company acquired by
Endo Pharmaceuticals, Inc. in January
2015. Under Mr. Anido's leadership at Auxilium, sales grew
from $42 million in 2005 to more than
$260 million in 2011. Prior to
Auxilium, Mr. Anido served as Executive Vice President, Sales and
Marketing, at MedImmune, where Synagis, an anti-viral for RSV,
became a blockbuster product, and prior to that, in senior sales
and marketing positions at GlaxoWellcome and Lederle Laboratories.
At Lederle, he was Vice President, Anti-Infectives, responsible for
the commercialization of the anti-bacterials, Suprax and Zosyn. He
is currently a member of the Board of Directors of AURIS Medical
Holding AG and Life Science PA, and he was a member of the Board of
Directors of Adolor Corporation until it was sold to Cubist
Pharmaceuticals in December 2011. Mr.
Anido earned a BS in Pharmacy and an MBA from West Virginia University.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ:SCYX)
is a biotechnology company committed to positively impacting the
lives of patients suffering from difficult-to-treat and often
life-threatening infections by developing innovative therapies.
The SCYNEXIS team has extensive experience in the
life sciences industry, having discovered and developed more than
30 innovative medicines over a broad range of therapeutic areas.
The Company's lead product candidate, ibrexafungerp (formerly
known as SCY-078), is a novel IV/oral antifungal agent in Phase 3
clinical and preclinical development for the treatment of multiple
serious and life-threatening invasive fungal infections caused by
Candida and Aspergillus species. For more
information, visit www.scynexis.com.
Forward Looking Statement
Statements contained in this
press release regarding expected future events or results are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, but are not
limited, to: risks inherent in SCYNEXIS's ability to
successfully develop and obtain FDA approval for
ibrexafungerp; the expected costs of studies and when they might
begin or be concluded; and SCYNEXIS's reliance on third
parties to conduct SCYNEXIS's clinical studies. These and
other risks are described more fully
in SCYNEXIS's filings with the Securities and
Exchange Commission, including without limitation, its most recent
Annual Report on Form 10-K under the caption "Risk Factors" and
other documents subsequently filed with or furnished to
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. SCYNEXIS undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
CONTACT:
Investor Relations
Natalie
Wildenradt
Argot Partners
Tel: 212-600-1902
natalie@argotpartners.com
Media Relations
George E.
MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-announces-appointment-of-industry-veteran-armando-anido-to-its-board-of-directors-300781836.html
SOURCE SCYNEXIS, Inc.